New technique could be used to choose best therapies for patients and measure their effectiveness
Evaluating the effectiveness of therapies for neurodegenerative diseases is often difficult because each patient’s progression is different. A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients.
A new study, published today in Nature Structural & Molecular Biology, moves researchers closer to understanding one of the crucial proteins involved in Parkinson’s disease.
Dr. Peter McPherson, James McGill Professor of Neurology and Neurosurgery, and Anatomy and Cell Biology at the Montreal Neurological Institute, McGill University has been named a Fellow of the Royal Society of Canada (RSC).
The Montreal Neurological Institute and Hospital - The Neuro, McGill University and the McGill University Health Centre, is at the forefront of Parkinson’s research and clinical care. Parkinson’s patients are seen at The Neuro’s Movement Disorders Clinic and the Montreal General Hospital. Approximately 100,000 Canadians have Parkinson’s disease.
New Rapid-Access Clinic at The Neuro reduces wait time
Mechanism meant to maintain efficiency of brain network involved in neurodegenerative disease
